- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Adaptimmune Therapeutics Plc (ADAP)
Adaptimmune Therapeutics Plc stock price live, this page displays NASDAQ ADAP stock exchange data. View the ADAP premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Adaptimmune Therapeutics Plc real time stock price chart below.
What Is the Adaptimmune Therapeutics Plc Stock Price Today?
The Adaptimmune Therapeutics Plc stock price today is 0.059.
What Is the Stock Symbol for Adaptimmune Therapeutics Plc?
The stock symbol for Adaptimmune Therapeutics Plc is ""ADAP.""
What Stock Exchange Does Adaptimmune Therapeutics Plc Trade On?
Adaptimmune Therapeutics Plc is listed and trades on the NASDAQ stock exchange.
Is Adaptimmune Therapeutics Plc a Good Stock to Buy?
Determining whether Adaptimmune Therapeutics Plc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ADAP quote. (ISIN: US00653A1079)
What Is the Adaptimmune Therapeutics Plc Stock Price Today?
The Adaptimmune Therapeutics Plc stock price today is 0.059.
What Is the Stock Symbol for Adaptimmune Therapeutics Plc?
The stock symbol for Adaptimmune Therapeutics Plc is ""ADAP.""
What Stock Exchange Does Adaptimmune Therapeutics Plc Trade On?
Adaptimmune Therapeutics Plc is listed and trades on the NASDAQ stock exchange.
Is Adaptimmune Therapeutics Plc a Good Stock to Buy?
Determining whether Adaptimmune Therapeutics Plc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ADAP quote. (ISIN: US00653A1079)
Fair Value
An estimate of a Adaptimmune Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.059
0.067
52 wk Range
0.052
1.320
ADAP Scorecard
Full Analysis
Quickly burning through cash
ADAP is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Adaptimmune Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.0590.067
52 wk Range
0.0521.320
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ADAP Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Adaptimmune Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
0.683
Upside
+1,058.19%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
- Form 13G Adaptimmune Therapeutics PLC For: 13 August
- Investing.com
- Form 13G Adaptimmune Therapeutics PLC For: 13 August
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Adaptimmune Therapeutics Plc Company Profile
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos’ decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Adaptimmune Therapeutics Plc SWOT Analysis
TCR-T Breakthrough | Adaptimmune's early FDA approval of Tecelra for synovial sarcoma marks a significant milestone in T-cell receptor engineered therapies |
Financial Crossroads | Despite impressive revenue growth, Adaptimmune faces challenges with negative EPS forecasts and a revised cash runway extending into late 2025 |
Market Dynamics | Explore Adaptimmune's pioneering position in the TCR-T market, balanced against the $727,000 list price for Tecelra and potential adoption hurdles |
Future Prospects | Analyst price targets hover around $1.00, reflecting cautious optimism as Adaptimmune navigates commercialization challenges and pipeline development |
Adaptimmune Therapeutics Plc Earnings Call Summary for Q1/2025
- Q2 2025 revenue beat at $13.67M, 22.16% above forecast; EPS of -$0.02 better than expected -$0.05
- Stock dipped 5.08% pre-market to $0.0729, despite revenue beat, reflecting investor concerns
- Full-year revenue guidance of $35M-$45M from TESULRA sales; preparing for Leticel launch in 2026
- 100% manufacturing success rate highlighted; cash runway less than 12 months poses sustainability risk
- Financial health score 'WEAK' at 1.11; negative free cash flow yield of -12.69% and Altman Z-Score of -33.7
Last Updated: 21/08/2025, 12:52
Read Full TranscriptCompare ADAP to Peers and Sector
Metrics to compare | ADAP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipADAPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.1x | −1.4x | −0.5x | |
PEG Ratio | 0.00 | −0.05 | 0.00 | |
Price/Book | −0.2x | 1.1x | 2.6x | |
Price / LTM Sales | 0.2x | 9.0x | 3.3x | |
Upside (Analyst Target) | - | 201.8% | 38.9% | |
Fair Value Upside | Unlock | 41.4% | 5.4% | Unlock |
Analyst Ratings
0 Buy
3 Hold
1 Sell
Ratings:
4 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 0.683
(+1,058.19% Upside)
Earnings
Latest Release
Aug 13, 2025
EPS / Forecast
-0.02 / -0.05
Revenue / Forecast
13.67M / 11.19M
People Also Watch
FAQ
What Stock Exchange Does Adaptimmune Therapeutics Trade On?
Adaptimmune Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Adaptimmune Therapeutics?
The stock symbol for Adaptimmune Therapeutics is "ADAP."
What Is the Adaptimmune Therapeutics Market Cap?
As of today, Adaptimmune Therapeutics market cap is 15.61M.
What Is Adaptimmune Therapeutics's Earnings Per Share (TTM)?
The Adaptimmune Therapeutics EPS (TTM) is -0.66.
When Is the Next Adaptimmune Therapeutics Earnings Date?
Adaptimmune Therapeutics will release its next earnings report on 04 Nov 2025.
From a Technical Analysis Perspective, Is ADAP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Adaptimmune Therapeutics Stock Split?
Adaptimmune Therapeutics has split 0 times.
How Many Employees Does Adaptimmune Therapeutics Have?
Adaptimmune Therapeutics has 506 employees.
What is the current trading status of Adaptimmune Therapeutics (ADAP)?
As of 30 Aug 2025, Adaptimmune Therapeutics (ADAP) is trading at a price of 0.059, with a previous close of 0.07. The stock has fluctuated within a day range of 0.059 to 0.067, while its 52-week range spans from 0.052 to 1.320.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.